Life sciences glossary I–N

The following Life Sciences practice note provides comprehensive and up to date legal information covering:

  • Life sciences glossary I–N
  • Immunological medicinal product
  • In vitro diagnostic medical device
  • Indication
  • Informed consent
  • International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)
  • International Nonproprietary Name (INN)
  • International Union for the Protection of New Varieties of Plants (UPOV)
  • Invented name
  • Investigational medicinal product (IMP)
  • More...

Life sciences glossary I–N

IP COMPLETION DAY: 11pm (GMT) on 31 December 2020 marks the end of the Brexit transition/implementation period entered into following the UK’s withdrawal from the EU. At this point in time (referred to in UK law as ‘IP completion day’), key transitional arrangements come to an end and significant changes begin to take effect across the UK’s legal regime. This document contains guidance on subjects impacted by these changes. Before continuing your research, see Practice Note: What does IP completion day mean for Life Sciences?

A–B | C–D | E–H | O–P | Q–U.

Immunological medicinal product

Article 1(4) of Directive 2001/83/EC (consolidated version 26.07.2019), the Pharmaceutical Code defines immunological medicinal product as:

‘Any medicinal product consisting of vaccines, toxins, serums or allergen products: (a) vaccines, toxins and serums shall cover in particular: (i) agents used to produce active immunity, such as cholera vaccine, BCG, polio vaccines, smallpox vaccine; (ii) agents used to diagnose the state of immunity, including in particular tuberculin and tuberculin PPD, toxins for the Schick and Dick Tests, brucellin; (iii) agents used to produce passive immunity, such as diphtheria antitoxin, anti-smallpox globulin, antilymphocytic globulin; (b) “allergen product” shall mean any medicinal product which is intended to identify or induce a specific acquired alteration in the immunological response to an allergizing agent.’

In vitro diagnostic medical device

Article 1(2)(b) of Directive 98/79/EC (consolidated version

Related documents:

Popular documents